Zoran Culig

Zoran Culig

UNVERIFIED PROFILE

Are you Zoran Culig?   Register this Author

Register author
Zoran Culig

Zoran Culig

Publications by authors named "Zoran Culig"

Are you Zoran Culig?   Register this Author

99Publications

1380Reads

24Profile Views

Epithelial mesenchymal transition and resistance in endocrine-related cancers.

Authors:
Zoran Culig

Biochim Biophys Acta Mol Cell Res 2019 Sep 18;1866(9):1368-1375. Epub 2019 May 18.

Experimental Urology, Department of Urology, Medical University of Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbamcr.2019.05.003DOI Listing
September 2019

Centrosomal Proteins in Urothelial Tumors: New Pathways in Disease Pathogenesis.

Authors:
Zoran Culig

Am J Pathol 2019 Jun 13;189(6):1178-1179. Epub 2019 Apr 13.

Section of Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajpath.2019.04.002DOI Listing
June 2019

Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review.

Gerontology 2019 3;65(5):458-464. Epub 2019 Apr 3.

Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496289DOI Listing
April 2019

Studies on Steroid Receptor Coactivators in Prostate Cancer.

Methods Mol Biol 2018 ;1786:259-262

Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-7845-8_15DOI Listing
February 2019

Identification of Potential Novel Candidates for Understanding Racial Differences in Prostate Cancer.

Authors:
Zoran Culig

Eur Urol 2019 01 4;75(1):16-17. Epub 2018 Oct 4.

Department of Urology, Innsbruck Medical University, Innsbruck, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.09.038DOI Listing
January 2019

Fractionated Radiation of Primary Prostate Basal Cells Results in Downplay of Interferon Stem Cell and Cell Cycle Checkpoint Signatures.

Eur Urol 2018 12 18;74(6):847-849. Epub 2018 Jun 18.

Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Innsbruck, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.06.002DOI Listing
December 2018

The way towards understanding possible multiple functions of AR V7 in prostate cancer.

Authors:
Zoran Culig

BJU Int 2018 08;122(2):169

Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.14406DOI Listing
August 2018

Correction Alternative mechanisms of miR-34a regulation in cancer.

Cell Death Dis 2018 Jul 16;9(8):783. Epub 2018 Jul 16.

Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41419-018-0833-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048027PMC
July 2018

Interleukin-4 induces a CD44 /CD49b PC3 subpopulation with tumor-initiating characteristics.

J Cell Biochem 2018 05 19;119(5):4103-4112. Epub 2018 Jan 19.

Division of Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.26607DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900863PMC
May 2018

Interleukin-6 and prostate cancer: Current developments and unsolved questions.

Mol Cell Endocrinol 2018 02 16;462(Pt A):25-30. Epub 2017 Mar 16.

Experimental Urology, Department of Urology, Medical University of Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mce.2017.03.012DOI Listing
February 2018

Innovative Therapies to Overcome Resistance to Enzalutamide: Perspective on the Use of Darolutamide.

Authors:
Zoran Culig

Eur Urol 2018 01 8;73(1):9-10. Epub 2017 Sep 8.

Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.08.024DOI Listing
January 2018

The "Aging Factor" Eotaxin-1 (CCL11) Is Detectable in Transfusion Blood Products and Increases with the Donor's Age.

Front Aging Neurosci 2017 1;9:402. Epub 2017 Dec 1.

Department of Anesthesiology and Critical Care Medicine, University Hospital of Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fnagi.2017.00402DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5717008PMC
December 2017

Alternative mechanisms of miR-34a regulation in cancer.

Cell Death Dis 2017 10 12;8(10):e3100. Epub 2017 Oct 12.

Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/cddis.2017.495DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682661PMC
October 2017

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer.

Authors:
Zoran Culig

Curr Mol Biol Rep 2017 23;3(4):230-235. Epub 2017 Oct 23.

Experimental Urology, Department of Urology, Medical University of Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40610-017-0079-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700216PMC
October 2017

Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer.

Cancer Immunol Immunother 2017 Apr 22;66(4):427-440. Epub 2016 Dec 22.

Department of Urology, Research Group of Urologic Oncology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-016-1945-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359386PMC
April 2017

Predictive and prognostic role of serum neopterin and tryptophan breakdown in prostate cancer.

Cancer Sci 2017 Apr 12;108(4):663-670. Epub 2017 Apr 12.

Division of Biological Chemistry, Biocenter, Medical University Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13171DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406598PMC
April 2017

STAT3 in Prostate Cancer: Whom Should We Treat and When?

Authors:
Zoran Culig

Eur Urol 2017 03 9;71(3):317-318. Epub 2016 Jul 9.

Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2016.06.034DOI Listing
March 2017

The role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel-resistant prostate cancer.

Mol Oncol 2017 03 30;11(3):251-265. Epub 2017 Jan 30.

UCD School of Medicine, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/1878-0261.12030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527446PMC
March 2017

The Molecular Evolution of Castration-resistant Prostate Cancer.

Eur Urol Focus 2016 Dec 9;2(5):506-513. Epub 2016 Dec 9.

Prostate Cancer Research Center, Institute of Biosciences and Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2016.11.012DOI Listing
December 2016

JAK-STAT signaling in cancer: From cytokines to non-coding genome.

Cytokine 2016 11 24;87:26-36. Epub 2016 Jun 24.

Clinical Institute of Pathology, Medical University of Vienna, 1090 Vienna, Austria; Ludwig Boltzmann Institute for Cancer Research, Medical University of Vienna, 1090 Vienna, Austria; Department for Pathology of Laboratory Animals, University of Veterinary Medicine Vienna, 1210 Vienna, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cyto.2016.06.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059362PMC
November 2016

Inflammation, Microbiota, and Prostate Cancer.

Eur Urol Focus 2016 Oct 28;2(4):374-382. Epub 2016 Aug 28.

Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2016.08.010DOI Listing
October 2016

IL-6/STAT3/ARF: the guardians of senescence, cancer progression and metastasis in prostate cancer.

Swiss Med Wkly 2015 21;145:w14215. Epub 2015 Dec 21.

Ludwig Boltzmann Institute for Cancer Research, Medical University of Vienna, Austria; Clinical Institute of Pathology, Medical University of Vienna, Austria; Depatment of Pathology of Laboratory Animals (UPLA), University of Veterinary Medicine Vienna, A.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4414/smw.2015.14215DOI Listing
September 2016

SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells.

Mol Cancer Res 2016 06 6;14(6):574-85. Epub 2016 Apr 6.

Division of Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-15-0495DOI Listing
June 2016

The AR/NCOA1 axis regulates prostate cancer migration by involvement of PRKD1.

Endocr Relat Cancer 2016 06 2;23(6):495-508. Epub 2016 Jun 2.

Division of Experimental UrologyDepartment of Urology, Medical University of Innsbruck, Innsbruck, Austria

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-16-0160DOI Listing
June 2016

Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.

Oncotarget 2016 Jun;7(26):39916-39930

Department of Pathology, Division of General Pathology, Medical University of Innsbruck, A-6020 Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.9537DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129981PMC
June 2016

New possibilities for urinary molecular diagnostics.

Authors:
Zoran Culig

BJU Int 2016 Apr;117(4):547-8

Experimental Urology, Department of Urology, Medical University of Innsbruck, Anichstrasse 35, Innsbruck, A-6020, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.13233DOI Listing
April 2016

Breaking a paradigm: IL-6/STAT3 signaling suppresses metastatic prostate cancer upon ARF expression.

Mol Cell Oncol 2016 Mar 4;3(2):e1090048. Epub 2016 Apr 4.

Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria; Unit of Pathology of Laboratory Animals (UPLA), University of Veterinary Medicine Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/23723556.2015.1090048DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905394PMC
March 2016

High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer.

J Mol Biochem 2016 Mar;5(1):12-22

Turku Centre for Biotechnology, University of Turku, Finland; Medical Biotechnology, VTT Technical Research Centre of Finland, Finland.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120689PMC
March 2016

Androgen Receptor Coactivators in Regulation of Growth and Differentiation in Prostate Cancer.

Authors:
Zoran Culig

J Cell Physiol 2016 Feb;231(2):270-4

Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.25099DOI Listing
February 2016

Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer.

Endocr Relat Cancer 2016 Jan 19;23(1):35-45. Epub 2015 Oct 19.

Department of UrologyLeiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The NetherlandsDepartment of Targeted TherapeuticsMIRA Institute for Biological Technology and Technical Medicine, University of Twente, Enschede, The NetherlandsDepartment of UrologyMedical University of Innsbruck, Innsbruck, AustriaDepartment of Clinical OncologyLeiden University Medical Center, Leiden, The NetherlandsDivision of Experimental MedicineImperial College London, London, UKDepartment of PharmaceuticsUtrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The NetherlandsDepartment of EndocrinologyLeiden University Medical Center, Leiden, The Netherlands

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-15-0343DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657186PMC
January 2016

Is Eotaxin-1 a serum and urinary biomarker for prostate cancer detection and recurrence?

Prostate 2015 Dec 26;75(16):1904-9. Epub 2015 Aug 26.

Department of Urology, Medical University of Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23086DOI Listing
December 2015

The Role of Biomarkers and Genetics in the Diagnosis of Prostate Cancer.

Eur Urol Focus 2015 Sep 28;1(2):99-108. Epub 2015 Aug 28.

Radboud University Medical Center, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2015.08.001DOI Listing
September 2015

ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat.

EMBO Mol Med 2015 Jun;7(6):831-47

Experimental Medicine I, Nikolaus-Fiebiger-Center for Molecular Medicine, FAU University Erlangen-Nürnberg, Erlangen, Germany German Cancer Consortium (DKTK), Freiburg and German Cancer Research Center (DKFZ), Heidelberg, Germany

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15252/emmm.201404396DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459821PMC
June 2015

Epithelial-to-mesenchymal transition in a virally induced cancer.

Authors:
Zoran Culig

J Urol 2015 Feb 13;193(2):396-7. Epub 2014 Nov 13.

Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2014.11.011DOI Listing
February 2015

Launching of american journal of clinical and experimental urology.

Am J Clin Exp Urol 2013 25;1(1):1-2. Epub 2013 Dec 25.

University of Washington Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219280PMC
November 2014

TMPRSS:ERG fusion in prostate cancer: from experimental approaches to prognostic studies.

Authors:
Zoran Culig

Eur Urol 2014 Nov 13;66(5):861-2. Epub 2014 Apr 13.

Experimental Urology, Department of Urology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2014.03.045DOI Listing
November 2014

Proinflammatory cytokine interleukin-6 in prostate carcinogenesis.

Authors:
Zoran Culig

Am J Clin Exp Urol 2014 2;2(3):231-8. Epub 2014 Oct 2.

Experimental Urology, Department of Urology, Innsbruck Medical University Anichstrasse 35, A-6020 Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219316PMC
November 2014

Androgen receptor signaling in prostate cancer.

Cancer Metastasis Rev 2014 Sep;33(2-3):413-27

Division of Experimental Urology, Department of Urology, Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-013-9474-0DOI Listing
September 2014

Targeting the androgen receptor in prostate cancer.

Authors:
Zoran Culig

Expert Opin Pharmacother 2014 Jul 2;15(10):1427-37. Epub 2014 Jun 2.

Innsbruck Medical University, Experimental Urology, Department of Urology , Anichstrasse 35, A-6020 Innsbruck , Austria +43 512 504 24717 ; +43 512 504 24817 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2014.915313DOI Listing
July 2014

Distinguishing indolent from aggressive prostate cancer.

Authors:
Zoran Culig

Recent Results Cancer Res 2014 ;202:141-7

Experimental Urology, Department of Urology, Innsbruck Medical University, Anichstrasse 35, A-6020, Innsbruck, Austria,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-642-45195-9_17DOI Listing
May 2014

Words of wisdom: Re: TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c.

Authors:
Zoran Culig

Eur Urol 2014 May;65(5):1011

Experimental Urology, Department of Urology, Innsbruck Medical University, Innsbruck, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2013.12.038DOI Listing
May 2014

Words of wisdom: Re: Lin28 promotes growth of prostate cancer cells and activates the androgen receptor.

Authors:
Zoran Culig

Eur Urol 2014 May;65(5):1013

Experimental Urology, Department of Urology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2013.12.040DOI Listing
May 2014

SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer.

Endocr Relat Cancer 2014 Apr 30;21(2):175-87. Epub 2014 Jan 30.

Experimental Urology, Department of Urology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria Oncotyrol Laboratory for Tumor Biology and Angiogenesis, Innsbruck, Austria Institute of Pathology, University Hospital Bonn, Bonn, Germany Division of Molecular Pathophysiology, Innsbruck Biocenter, Medical University Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-13-0446DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907181PMC
April 2014

The mutational landscape of prostate cancer.

Eur Urol 2013 Oct 18;64(4):567-76. Epub 2013 May 18.

Department of Urology, Weill Medical College of Cornell University, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2013.05.029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342117PMC
October 2013

Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer.

Steroids 2013 Sep 30;78(9):851-9. Epub 2013 Apr 30.

Division of Experimental Urology, Department of Urology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.steroids.2013.04.012DOI Listing
September 2013

CXCL8, an underestimated "bad guy" in prostate cancer.

Authors:
Zoran Culig

Eur Urol 2013 Aug 17;64(2):189-90; discussion 190-2. Epub 2012 Sep 17.

Experimental Urology, Department of Urology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2012.09.024DOI Listing
August 2013

Current mouse and cell models in prostate cancer research.

Endocr Relat Cancer 2013 Aug 24;20(4):R155-70. Epub 2013 Jun 24.

Department of Pathology, New York University School of Medicine, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-12-0285DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855867PMC
August 2013

Rapidly changing endocrine oncology research: personal reflection of the past, present and future times.

Authors:
Zoran Culig

Endocr Relat Cancer 2013 Apr 26;20(2):P7-9. Epub 2013 Mar 26.

Experimental Urology, Department of Urology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-12-0362DOI Listing
April 2013

Interleukin-6 as a therapy target in oral squamous carcinoma.

Authors:
Zoran Culig

Expert Opin Ther Targets 2013 Jan 27;17(1):53-9. Epub 2012 Oct 27.

Experimental Urology, Department of Urology, Anichstrasse 35, A-6020 Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728222.2013.733368DOI Listing
January 2013

Suppressors of cytokine signalling-3 and -1 in human carcinogenesis.

Authors:
Zoran Culig

Front Biosci (Schol Ed) 2013 Jan 1;5:277-83. Epub 2013 Jan 1.

Department of Urology, Experimental Urology, Innsbruck Medical University, Innsbruck, Austria.

View Article

Download full-text PDF

Source
January 2013

Genetic markers in prostate cancer: progress and limitations.

Authors:
Zoran Culig

Eur Urol 2012 Oct 27;62(4):588-9. Epub 2012 Jun 27.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2012.06.040DOI Listing
October 2012

Interleukin-6: a multifunctional targetable cytokine in human prostate cancer.

Mol Cell Endocrinol 2012 Sep 1;360(1-2):52-8. Epub 2011 Jun 1.

Department of Urology, Experimental Urology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mce.2011.05.033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409376PMC
September 2012

Androgen receptor co-activators in the regulation of cellular events in prostate cancer.

World J Urol 2012 Jun 22;30(3):297-302. Epub 2011 Nov 22.

Experimental Urology, Department of Urology, Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-011-0797-6DOI Listing
June 2012

Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways.

Endocr Relat Cancer 2012 Jun 3;19(3):305-19. Epub 2012 May 3.

Division of Experimental Urology, Department of Urology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-11-0298DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353237PMC
June 2012

Involvement of interleukin-1β mediated nuclear factor κB signalling pathways to down-regulate prostate-specific antigen and cell proliferation in LNCaP prostate cancer cells.

Cell Biol Int 2012 May;36(5):449-54

Unit of ImmunoMicrobio Environmental and Carcinogenesis, Faculty of Sciences of Bizerte, University of Carthage, 7021, Zarzouna, Bizerte, Tunisia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1042/CBI20100922
Publisher Site
http://dx.doi.org/10.1042/CBI20100922DOI Listing
May 2012

PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21.

Am J Pathol 2012 May 23;180(5):2097-107. Epub 2012 Mar 23.

Experimental Urology, Department of Urology, Innsbruck Medical University, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajpath.2012.01.026DOI Listing
May 2012

Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner.

J Urol 2011 Nov 23;186(5):2107-14. Epub 2011 Sep 23.

Division of Medical Oncology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2011.06.048DOI Listing
November 2011

SOCS-3 antagonizes pro-apoptotic effects of TRAIL and resveratrol in prostate cancer cells.

Prostate 2011 Sep 9;71(12):1357-66. Epub 2011 Feb 9.

Department of Urology, Innsbruck Medical University, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.21353DOI Listing
September 2011

IL-6 causes multiple effects in androgen-sensitive and -insensitive prostate cancer cell lines.

Authors:
Zoran Culig

Expert Rev Endocrinol Metab 2011 May;6(3):327-332

a Department of Urology, Experimental Urology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/eem.11.34DOI Listing
May 2011

Transcriptional coactivators p300 and CBP stimulate estrogen receptor-beta signaling and regulate cellular events in prostate cancer.

Prostate 2011 Mar 21;71(4):431-7. Epub 2010 Sep 21.

Department of Urology, Innsbruck Medical University, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.21257DOI Listing
March 2011

Cytokine disbalance in common human cancers.

Authors:
Zoran Culig

Biochim Biophys Acta 2011 Feb 15;1813(2):308-14. Epub 2010 Dec 15.

Department of Urology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbamcr.2010.12.010DOI Listing
February 2011

Role of the protein tyrosine phosphatase SHP-1 in Interleukin-6 regulation of prostate cancer cells.

Prostate 2010 Oct;70(14):1491-500

Department of Laboratory Medicin, Tumour Biology, Lund University, Malmö University Hospital, Malmö, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.21184DOI Listing
October 2010

SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling.

Endocr Relat Cancer 2010 Jun 18;17(2):525-38. Epub 2010 May 18.

Department of Urology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1677/ERC-10-0007DOI Listing
June 2010

Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells.

Endocr Relat Cancer 2010 Mar 18;17(1):241-53. Epub 2010 Feb 18.

Department of Urology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1677/ERC-09-0200DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829126PMC
March 2010

Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells.

Endocr Relat Cancer 2010 Mar 18;17(1):241-53. Epub 2010 Feb 18.

Department of Urology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1677/ERC-09-0200DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829126PMC
March 2010

New insights into the role of interleukin-6 in human prostate cancer.

Authors:
Zoran Culig

J Urol 2009 Oct 14;182(4):1255-6. Epub 2009 Aug 14.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2009.07.073DOI Listing
October 2009

Identification of mu-crystallin as an androgen-regulated gene in human prostate cancer.

Prostate 2009 Jul;69(10):1109-18

Department of Urology and Biocenter, Innsbruck Medical University, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.20956DOI Listing
July 2009

Differential involvement of reactive oxygen species and nucleoside transporters in cytotoxicity induced by two adenosine analogues in human prostate cancer cells.

Prostate 2009 Apr;69(5):538-47

Dipartimento di Medicina Sperimentale Scienze Biochimiche, Sezione Biochimica Cellulare, Perugia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.20900DOI Listing
April 2009

Oxidative stress-related aging: A role for prostate cancer?

Biochim Biophys Acta 2009 Apr 11;1795(2):83-91. Epub 2008 Dec 11.

Dipartimento di Medicina Sperimentale Scienze Biochimiche, Sezione Biochimica Cellulare, Università di Perugia, via del Giochetto, 06123 Perugia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbcan.2008.11.001DOI Listing
April 2009

Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.

Endocr Relat Cancer 2009 Mar 14;16(1):155-69. Epub 2008 Nov 14.

Department of Urology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1677/ERC-08-0174DOI Listing
March 2009

Oligomeric proanthocyanidin complexes (OPC) exert anti-proliferative and pro-apoptotic effects on prostate cancer cells.

Prostate 2008 Nov;68(15):1647-54

Department of Urology, Innsbruck Medical University, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.20829DOI Listing
November 2008

Re: stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70.

Authors:
Zoran Culig

Eur Urol 2008 Jun;53(6):1298

Department of Urology, Innsbruck Medical University, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2008.03.023DOI Listing
June 2008

2-chloroadenosine modulates PAR-1 and IL-23 expression and enhances docetaxel effects on PC3 cells.

Prostate 2008 Mar;68(4):360-72

Dipartimento di Medicina Sperimentale Scienze Biochimiche, Sezione Biochimica Cellulare, via del Giochetto, Perugia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.20703DOI Listing
March 2008